When I first discovered that a strain of sweet tooth bacteria could turn fat and unhealthy, I was skeptical.
But I was pleasantly surprised.
The strain that’s causing the problem is called Toxoplasma Gontas, and it’s known for producing the dreaded obesity gene, TIGER.
The T.G.E.A.S. strain has been found in mice, and researchers think it’s a key player in the development of obesity.
The new strain is resistant to all of the major antibiotics and is able to survive for weeks without food, so it could potentially be a long-term treatment option for some people with metabolic syndrome, or obesity.
And it’s not just a matter of taking a pill every day.
A study published in the journal Nature Communications found that T. G.
E and Toxo-Gontas can help people who are overweight or obese manage their weight without medication.
The researchers used an innovative new method of measuring metabolism that combines the body’s own biological clock with measurements of a metabolic biomarker called metabolic homeostasis index.
This type of biomarker can show the health status of the body and help scientists understand why certain genes and hormones have the potential to impact a person’s weight.
This new method allows researchers to compare two populations of people at different stages of weight management.
The first group is treated with T. gontas bacteria and a pill to control their metabolic syndrome.
The second group receives Toxol-Goc and is given a pill that has the same metabolic biomarkers as T. O.G., which is the strain that causes T.O.
G in humans.
This combination allows researchers and scientists to compare the metabolic homeosome—the metabolic information in the body that tells the body when it’s time to shut down and what its metabolic output should be like.
The team found that the T.g.
E-infected group had significantly higher levels of Toxopro-O-Glutamine (TGEO) in their blood than did the Toxogoc-O (GO) group.
These researchers say that these results suggest that Tox O. Gonta can potentially improve metabolic health in people with obesity and metabolic syndrome in the future.